AbbVie Completes Acquisition of Aliada Therapeutics
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer’s disease, ALIA-1758, and novel blood-brain barrier (BBB)-crossing technology to strengthen neuroscience pipeline and R&D capabilities NORTH CHICAGO, ILL. – AbbVie (NYSE: ABBV)… Read More




